CryoCell International Ownership
| CCEL Stock | USD 7.79 0.17 2.23% |
Shares in Circulation | First Issued 1996-03-31 | Previous Quarter 8.2 M | Current Value 8.2 M | Avarage Shares Outstanding 9.7 M | Quarterly Volatility 1.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
CryoCell |
CryoCell Stock Ownership Analysis
About 48.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.07. CryoCell International last dividend was issued on the 14th of February 2025. Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida. Cryo-Cell Intl operates under Medical Care Facilities classification in the United States and is traded on AMEX Exchange. It employs 83 people. For more info on CryoCell International please contact Mark Portnoy at 813 749 2100 or go to https://www.cryo-cell.com.Besides selling stocks to institutional investors, CryoCell International also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different CryoCell International's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align CryoCell International's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
CryoCell International Quarterly Liabilities And Stockholders Equity |
|
CryoCell International Insider Trades History
About 48.0% of CryoCell International are currently held by insiders. Unlike CryoCell International's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against CryoCell International's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of CryoCell International's insider trades
CryoCell Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as CryoCell International is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CryoCell International backward and forwards among themselves. CryoCell International's institutional investor refers to the entity that pools money to purchase CryoCell International's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-09-30 | 249 | Bank Of America Corp | 2024-09-30 | 33.0 | Jpmorgan Chase & Co | 2024-09-30 | 11.0 | Rowland & Co Investment Counsel | 2024-09-30 | 0.0 | Royal Bank Of Canada | 2024-09-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Hamilton Lane Advisors Llc | 2024-09-30 | 409.7 K | Sfi Advisors, Llc | 2024-09-30 | 165.3 K | Vanguard Group Inc | 2024-09-30 | 116.8 K | Massmutual Trust Co Fsb/adv | 2024-09-30 | 111 K | Geode Capital Management, Llc | 2024-09-30 | 39.9 K |
CryoCell International Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CryoCell International insiders, such as employees or executives, is commonly permitted as long as it does not rely on CryoCell International's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CryoCell International insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
CryoCell International Outstanding Bonds
CryoCell International issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. CryoCell International uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CryoCell bonds can be classified according to their maturity, which is the date when CryoCell International has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
CryoCell International Corporate Filings
F4 | 23rd of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 27th of December 2024 Other Reports | ViewVerify | |
| 12th of November 2024 Other Reports | ViewVerify | |
8K | 31st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in CryoCell International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. If investors know CryoCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CryoCell International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.625 | Earnings Share (1.07) | Revenue Per Share | Quarterly Revenue Growth 0.025 | Return On Assets |
The market value of CryoCell International is measured differently than its book value, which is the value of CryoCell that is recorded on the company's balance sheet. Investors also form their own opinion of CryoCell International's value that differs from its market value or its book value, called intrinsic value, which is CryoCell International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CryoCell International's market value can be influenced by many factors that don't directly affect CryoCell International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CryoCell International's value and its price as these two are different measures arrived at by different means. Investors typically determine if CryoCell International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CryoCell International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.